tiprankstipranks
Trending News
More News >
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Advertisement

Ironwood Pharma (IRWD) AI Stock Analysis

Compare
321 Followers

Top Page

IRWD

Ironwood Pharma

(NASDAQ:IRWD)

Rating:46Neutral
Price Target:
$1.00
▼(-15.25% Downside)
Ironwood Pharma's overall stock score is primarily impacted by its challenging financial performance and valuation concerns. The potential delisting risk due to the Nasdaq deficiency letter further exacerbates the negative outlook. While there are some positive technical signals, they are overshadowed by the financial and corporate event risks.
Positive Factors
Financial Performance
Linzess revenues of $248M for 2Q25 appear on track to meet guidance of $800-850M and reflect normalization of gross-to-net accounting fluctuations.
Revenue Guidance
Management expects the rest of the year to show similar strength as 2Q, with guidance for $260-290M total revenue and adjusted EBITDA greater than $105M reiterated.
Negative Factors
Debt Challenges
The high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.
Regulatory Setbacks
An additional confirmatory Phase 3 trial for apraglutide in short bowel syndrome is needed for approval, adding financial uncertainty to the company.

Ironwood Pharma (IRWD) vs. SPDR S&P 500 ETF (SPY)

Ironwood Pharma Business Overview & Revenue Model

Company DescriptionIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
How the Company Makes MoneyIronwood generates revenue primarily through the sales of its commercialized products, with Linzess being the most significant contributor to its earnings. The company operates on a revenue model that includes direct product sales, as well as potential royalties and milestone payments from partnerships and collaborations with other pharmaceutical companies. Ironwood has established strategic collaborations to enhance its product pipeline and expand market reach, which can further augment its revenue through shared developments and co-promotion agreements. Additionally, the company may benefit from reimbursement agreements with healthcare providers and payers, which facilitate patient access to its therapies and support revenue growth.

Ironwood Pharma Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q4-2024)
|
% Change Since: 47.50%|
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong demand growth for LINZESS and promising data for apraglutide, suggesting potential future growth. However, concerns about pricing headwinds from Medicare Part D redesign and cash liquidity tempered the overall outlook.
Q4-2024 Updates
Positive Updates
Apraglutide's Potential for Market Expansion
The data from the STARS Extend study showed that 27 patients achieved enteral autonomy, reinforcing apraglutide's potential as a blockbuster therapy for short bowel syndrome. The NDA submission is expected to be completed by the third quarter of 2025.
LINZESS Demand Growth
LINZESS saw a 12% increase in prescription demand growth in Q4 2024 compared to Q4 2023. For the full year 2024, there was an 11% prescription demand growth year-over-year, and new-to-brand volume growth was 14%.
Financial Performance and Guidance
Ironwood achieved its 2024 financial guidance with $916 million in net sales. The company expects continued strong demand growth for LINZESS in 2025, despite anticipated pricing headwinds.
Debt Reduction Efforts
Ironwood reduced its total debt balance by approximately $115 million in 2024, ending the year with $385 million drawn on its credit facility.
Negative Updates
Pricing Headwinds Due to Medicare Part D Redesign
The redesign of Medicare Part D, which went into effect earlier this year, poses a pricing headwind for LINZESS, potentially impacting revenue despite strong demand.
Cash and Liquidity Concerns
Ironwood ended 2024 with $88.6 million in cash and cash equivalents, which may be seen as limited given the company's debt obligations and the need to fund apraglutide's launch.
Company Guidance
During the Ironwood Pharmaceuticals Fourth Quarter 2024 Investor Update Conference Call, the company provided guidance for the upcoming year. They expect U.S. LINZESS net sales to range between $800 million and $850 million, forecasting high single-digit prescription demand growth despite potential pricing headwinds due to Medicare Part D redesign. Ironwood anticipates total revenue between $260 million and $290 million and adjusted EBITDA, excluding stock-based compensation, to exceed $85 million. The company aims to complete the NDA submission for apraglutide by the third quarter of 2025, with prelaunch activities underway for its potential commercialization. Ironwood reported $916 million in LINZESS net sales for 2024 and projects its cash flows will support the development and launch of apraglutide, with a focus on delivering sustained profits and reducing debt. The company ended 2024 with $88.6 million in cash and cash equivalents and $385 million in debt, having repaid $115 million over the year.

Ironwood Pharma Financial Statement Overview

Summary
Ironwood Pharma faces a challenging financial landscape with declining revenues and profitability issues. The debt-laden balance sheet and negative equity highlight financial risk, while the cash flow provides a silver lining with positive free cash flow. Improvements in revenue generation and equity would be crucial for enhancing long-term financial health.
Income Statement
45
Neutral
The income statement reveals a mixed performance for Ironwood Pharma. Despite a high gross profit margin in TTM (99.69%), the company experienced a negative net profit margin (-9.89%) and revenue contraction compared to the previous year (-9.60%). The EBIT margin was moderate at 17.24%, reflecting some operational efficiency, but the negative net income indicates profitability challenges.
Balance Sheet
30
Negative
Ironwood Pharma's balance sheet shows significant financial stress. The company has a negative stockholders' equity (-$334 million) and an alarmingly high debt-to-equity ratio, indicating heavy reliance on debt financing. The equity ratio is negative, which poses a risk to financial stability.
Cash Flow
60
Neutral
The cash flow statement is relatively strong, with a positive free cash flow of $78.4 million in TTM, although the free cash flow growth rate is negative when compared to the previous annual period. The operating cash flow to net income ratio is positive, indicating that cash operations are healthier than income figures suggest.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue317.68M351.41M442.74M410.60M413.75M389.52M
Gross Profit286.86M343.86M442.74M409.18M412.23M298.32M
EBITDA60.23M100.24M-924.87M261.44M233.33M141.90M
Net Income-32.34M880.00K-1.00B175.06M528.45M106.18M
Balance Sheet
Total Assets327.21M350.91M471.07M1.10B1.13B559.24M
Cash, Cash Equivalents and Short-Term Investments108.48M88.56M92.15M656.20M620.13M362.56M
Total Debt599.08M599.48M715.54M415.92M475.80M453.70M
Total Liabilities661.27M652.24M817.37M448.14M521.02M496.60M
Stockholders Equity-334.05M-301.33M-346.30M652.38M605.91M62.64M
Cash Flow
Free Cash Flow78.41M103.41M183.15M273.63M261.63M166.99M
Operating Cash Flow78.52M103.55M183.43M273.76M261.89M168.84M
Investing Cash Flow-121.00K-142.00K-1.03B-136.00K-265.00K-1.84M
Financing Cash Flow-91.41M-106.97M277.16M-237.55M-4.55M18.55M

Ironwood Pharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.18
Price Trends
50DMA
0.81
Positive
100DMA
0.82
Positive
200DMA
1.93
Negative
Market Momentum
MACD
0.09
Negative
RSI
68.25
Neutral
STOCH
84.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRWD, the sentiment is Positive. The current price of 1.18 is above the 20-day moving average (MA) of 0.92, above the 50-day MA of 0.81, and below the 200-day MA of 1.93, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 68.25 is Neutral, neither overbought nor oversold. The STOCH value of 84.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRWD.

Ironwood Pharma Risk Analysis

Ironwood Pharma disclosed 45 risk factors in its most recent earnings report. Ironwood Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We may be unable to successfully integrate the business and personnel of VectivBio, and may not realize the expected benefits and anticipated synergies of such acquisition. Q4, 2023
2.
We cannot give any assurance that apraglutide will be successful in clinical trials, and if successful, will receive regulatory approval, which is necessary before it can be commercialized. Q4, 2023
3.
We may be unable to maintain the benefits associated with orphan drug designation, including market exclusivity, which may harm our business. Q4, 2023

Ironwood Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$411.31M23.44%-3.48%36.57%
58
Neutral
$75.50M-38.40%-11.42%89.01%
55
Neutral
$172.35M-57.22%-27.40%-475.41%
54
Neutral
$465.75M77.48%-24.38%-94.72%
53
Neutral
$46.08M-10.79%11.34%71.13%
51
Neutral
$7.77B-0.12-39.78%2.21%22.68%-1.42%
46
Neutral
$173.80M85.74-8.02%-22.98%-173.28%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IRWD
Ironwood Pharma
1.18
-3.80
-76.31%
ASRT
Assertio Therapeutics
0.77
-0.51
-39.84%
ESPR
Esperion
2.13
0.36
20.34%
CPIX
Cumberland Pharmaceuticals
3.24
1.86
134.78%
AQST
Aquestive Therapeutics
3.91
-0.55
-12.33%
DERM
Journey Medical Corp
7.08
2.25
46.58%

Ironwood Pharma Corporate Events

Executive/Board ChangesShareholder Meetings
Ironwood Pharma Elects Directors at Annual Meeting
Neutral
Jun 12, 2025

On June 10, 2025, Ironwood Pharmaceuticals held its Annual Meeting of Stockholders, where nine directors were elected to serve a one-year term on the board. Additionally, stockholders approved executive compensation and ratified Ernst & Young LLP as the independent public accounting firm for 2025.

Delistings and Listing ChangesRegulatory Filings and Compliance
Ironwood Pharma Receives Nasdaq Deficiency Letter
Negative
Jun 3, 2025

On May 28, 2025, Ironwood Pharmaceuticals received a deficiency letter from Nasdaq indicating that its Class A common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until November 24, 2025, to regain compliance, failing which it may face delisting or need to transfer its listing to the Nasdaq Capital Market. Ironwood intends to monitor its stock price and consider options to meet the requirement, though there is no assurance of success.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 08, 2025